Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 9:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2065–2088 of 35,409 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Alzheimer Disease
Interventions: Flortaucipir F18, Brain PET Scan, Whole body PET scan, Florbetapir F 18, Brain MRI; Drug · Procedure
Lead sponsor: Avid Radiopharmaceuticals; Industry
Eligibility: 20 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 2
States / cities: Cypress, California • Newport Beach, California

Conditions: Peripheral Vascular Interventions
Interventions: The LIBERTY® Robotic System; Device
Lead sponsor: Microbot Medical, INC; Industry
Eligibility: 22 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 3
States / cities: Miami, Florida • Boston, Massachusetts • New York, New York

Conditions: Myelodysplastic Syndromes
Interventions: Azacitidine; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Cerebral Palsy
Interventions: Physical and occupational therapy; Other
Lead sponsor: University of Arizona; Other
Eligibility: 12 Months to 36 Months
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 4
States / cities: Phoenix, Arizona • Tucson, Arizona • Orlando, Florida

Conditions: Adrenal Suppression
Interventions: Chemotherapy; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older · Female only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Childhood Acute Lymphoblastic Leukemia in Remission, Recurrent Childhood Acute Lymphoblastic Leukemia
Interventions: Laboratory Biomarker Analysis; Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 18 Years
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Mycobacterium Infections, Nontuberculous
Interventions: Liposomal amikacin for inhalation (LAI), placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 18
States / cities: Birmingham, Alabama • Stanford, California • Denver, Colorado + 15 more

Conditions: Dry Eye
Interventions: Eyelash prostheses, 5.0% Lifitegrast Ophthalmic Solution; Device
Lead sponsor: D.E.L., LLC; Industry
Eligibility: 50 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Washington, Missouri

Conditions: Grade I Meningioma, Adult, Grade II Meningioma, Adult, Grade III Meningioma, Adult, Recurrent Meningioma
Interventions: Pembrolizumab, Stereotactic Radiosurgery; Drug · Procedure
Lead sponsor: Nancy Ann Oberheim Bush, MD; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Bacterial Conjunctivitis
Interventions: AzaSite, Vehicle; Drug · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 12 Months and older
Enrollment: 685 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 32
States / cities: Flagstaff, Arizona • Cudahy, California • Petaluma and Santa Rosa, California + 27 more

Conditions: Anaplastic Astrocytoma, IDH-Wildtype, Glioblastoma, IDH-Wildtype, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Central Nervous System, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection - blood samples, Biospecimen Collection - CSF samples, Computed Tomography, EGFR/EGFRvIII Inhibitor WSD0922-FU, Magnetic Resonance Imaging, Therapeutic Conventional Surgery; Procedure · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2031
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Snake Bite, Blood Coagulation Disorders
Interventions: Anavip, CroFab; Biological
Lead sponsor: Instituto Bioclon S.A. de C.V.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Bronchitis, Bronchitis, Chronic
Interventions: Glycerol Guiacolate, SOC (Standard of care); Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 40 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Smoking
Interventions: Updating Existing Smartphone App, Quitline Services, Quitline Services and Smartphone App; Behavioral
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 1,051 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Staphylococcal Infections, Chronic Kidney Failure
Interventions: S. aureus Type 5 & 8 Capsular Polysaccharide Vaccine; Biological
Lead sponsor: Nabi Biopharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Madison, Alabama

Conditions: Glaucoma
Interventions: NT-501, Sham comparator; Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Healthy Participants
Interventions: AMG 510, Omeprazole; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Interventions: BI 4015092, Cetuximab; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 3
States / cities: New Haven, Connecticut • Dallas, Texas • Houston, Texas

Conditions: Early Literacy, Articulatory Gestures, Phonemic Awareness
Interventions: phonemic segmentation; Behavioral
Lead sponsor: Montclair State University; Other
Eligibility: 48 Months to 59 Months
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Montclair, New Jersey

Conditions: Morbid Obesity, Obstructive Sleep Apnea Syndrome, Metabolic Syndrome, Insulin Resistance, Nonalcoholic Fatty Liver Disease
Interventions: Laparoscopic adjustable gastric banding (Allergan Lap Band); Device
Lead sponsor: Jeffrey L Zitsman, MD; Other
Eligibility: 13 Years to 19 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Participants
Interventions: BLU-808, Placebo, Midazolam; Drug
Lead sponsor: Blueprint Medicines Corporation; Industry
Eligibility: 19 Years to 65 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Cervical Spine Fusion
Interventions: Anterior Cervical Discectomy & Fusion, Application of ADAM mechanoacoustic skin sensor; Procedure · Device
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 88 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Severe Combined Immunodeficiency
Interventions: unrelated BM with T cell depletion, unrelated cord blood, haplo BM with T cell depletion, unrelated PBSC with T cell depletion; Biological · Device
Lead sponsor: Neena Kapoor, M.D.; Other
Eligibility: Up to 21 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Safety Issues
Interventions: GB002, Generic Dry Powder Inhaler, Placebo; Drug · Device
Lead sponsor: GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

Exploratory Evaluation of Flortaucipir Injection in Healthy Volunteers and Cognitively Impaired Subjects

Assessment of Clin. Capabilities of LIBERTY® Endovascular Robotic System's Performance & Safety in Periph. Vasc. Interv.

A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes

Intense Physiotherapies to Improve Function in Young Children With Cerebral Palsy

Prevalence Study of Adrenal Suppression After Corticosteroids During Chemotherapy

DNA Analysis of Tumor Tissue Samples From Young Patients With Acute Lymphoblastic Leukemia

Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria

Eyelash Prostheses Compared to 5.0% Lifitegrast BID for Dry Eye Disease.

Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma

Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003)

WSD0922-FU for Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases

A Comparison of Crotalinae Equine Immune F(ab)2 Antivenom (Anavip) and Crotalidae Polyvalent Immune Fab,

Study to Evaluate the Effects of Oral Glyceryl Guiacolate (Guaifenesin, GGE) on Sputum Rheology in Subjects With Mucus Hypersecretion

App for Reducing Cravings to Smoke

Evaluation of Manufacturing Lot of StaphVAX

Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for Glaucoma

Study to Evaluate the Drug-drug Interaction Effect of Omeprazole on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants

A Study of BI 4015092, Alone or in Combination With Other Cancer Treatment, in Patients With Advanced Cancer That Has a KRAS G12D Mutation

The Effect of Articulatory Gestures on Early Literacy Skills in 4-year Olds

LAGB as a Treatment for Morbid Obesity in Adolescents

Study of BLU-808 in Healthy Adult Participants

Measuring Dysphagia After ACDF Surgery Through A Novel Wearable Sensor

SCID Bu/Flu/ATG Study With T Cell Depletion

Phase 1A Safety Trial of Inhaled PK10571 (GB002)